HWHong Wu

Hong Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Wu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Beilan Wang

    Shanghai-MOST Key Laboratory of Health and Disease Genomics, Department of Genetics, Chinese National Human Genome Center, Shanghai, China

    1 shared publication
  • Beixuan He

    Department of Pharmacognosy, College of Pharmacy, Naval Medical University (Second Military Medical University)

    1 shared publication
  • Bili Zhang

    Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China

    1 shared publication
  • Chaoqun Ma

    Department of Cardiology, Changhai Hospital, Naval Medical University, 168 Changhai Rd, Shanghai 200433, China

    1 shared publication
  • Dandan Guo

    Department of Pharmacognosy, College of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai, China

    1 shared publication
  • Fang Xie

    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Department of Genetics, Chinese National Human Genome Center, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    MiR-199a-3p deficiency induced by STAT3 activation drives smooth muscle cell phenotypic switching in pulmonary arterial hypertension

    by Wen-Xia He, Yun-Jie Huang, Tian-Hong Ai, Song-Qun Huang, Xiao-Hua You, Hong Wu, Xiao-Wei Song

    Pulmonary arterial hypertension (PAH) is a progressive vasculopathy characterized by pathological vascular remodeling, in which pulmonary artery smooth muscle cells (PASMCs) undergo phenotypic switching from a contractile to a synthetic state, driving excessive proliferation and migration. Here, we report that miR-199a-3p is significantly downregulated in both hypoxia/SU5416-induced PAH rat models and PDGF-BB-stimulated human PASMCs. Mechanistically, PDGF-BB stimulation induces the phosphorylation of STAT3, which directly binds to the TTCCCGGAA motif within the promoter of miR-199a-3p. This binding transcriptionally represses miR-199a-3p. Functional analyses demonstrated that miR-199a-3p overexpression maintains the PASMC contractile phenotype (upregulating MYH11 and SM22α) and suppresses proliferation and migration. Conversely, miR-199a-3p inhibition promotes synthetic phenotypic switching and activates the ERK/AKT signaling pathway. Furthermore, we identified YAP1 as a novel direct target of miR-199a-3p, linking miRNA downregulation to downstream proliferative signaling. Collectively, these findings establish a PDGF-BB/STAT3/miR-199a-3p/YAP1 regulatory axis that drives pathological PASMC phenotypic switching. This axis represents a promising therapeutic target for mitigating pulmonary vascular remodeling in PAH.

  • Open Access

    Both Two CtACO3 Transcripts Promoting the Accumulation of the Flavonoid Profiles in Overexpressed Transgenic Safflower

    by Beixuan He, Yanjie Zhang, Lunuan Wang, Dandan Guo, Xinlei Jia, Jianhui Wu, Shuyi Qi, Hong Wu, Yue Gao, Meili Guo

    The unique flavonoids, quinochalcones, such as hydroxysafflor yellow A (HSYA) and carthamin, in the floret of safflower showed an excellent pharmacological effect in treating cardiocerebral vascular disease, yet the regulating mechanisms governing the flavonoid biosynthesis are largely unknown. In this study,CtACO3, the key enzyme genes required for the ethylene signaling pathway, were found positively related to the flavonoid biosynthesis at different floret development periods in safflower and has twoCtACO3transcripts,CtACO3-1andCtACO3-2, and the latter was a splice variant ofCtACO3that lacked 5’ coding sequences. The functions and underlying probable mechanisms of the two transcripts have been explored. The quantitative PCR data showed thatCtACO3-1andCtACO3-2were predominantly expressed in the floret and increased with floret development. Subcellular localization results indicated thatCtACO3-1 was localized in the cytoplasm, whereasCtACO3-2 was localized in the cytoplasm and nucleus. Furthermore, the overexpression ofCtACO3-1 orCtACO3-2 in transgenic safflower lines significantly increased the accumulation of quinochalcones and flavonols. The expression of the flavonoid pathway genes showed an upward trend, withCtCHS1,CtF3H1,CtFLS1, andCtDFR1was considerably induced in the overexpression ofCtACO3-1orCtACO3-2lines. An interesting phenomenon forCtACO3-2 protein suppressing the transcription ofCtACO3-1might be related to the nucleus location ofCtACO3-2. Yeast two-hybrid (Y2H), glutathioneS-transferase (GST) pull-down, and BiFC experiments revealed thatCtACO3-2 interacted withCtCSN5a. In addition, the interactions betweenCtCSN5a andCtCOI1,CtCOI1 andCtJAZ1,CtJAZ1 andCtbHLH3 were observed by Y2H and GST pull-down methods, respectively. The above results suggested that theCtACO3-2 promoting flavonoid accumulation might be attributed to the transcriptional activation of flavonoid biosynthesis genes byCtbHLH3, whereas theCtbHLH3 might be regulated throughCtCSN5-CtCOI1-CtJAZ1 signal molecules. Our study provided a novel insight ofCtACO3 affected the flavonoid biosynthesis in safflower.


  • Open Access

    Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis

    by Chaoqun Ma, Jiawei Gu, Pan Hou, Liang Zhang, Yuan Bai, Zhifu Guo, Hong Wu, Bili Zhang, Pan Li, Xianxian Zhao

    Background: Recently, Coronavirus Disease 2019 (COVID-19) outbreak started in Wuhan, China. Although the clinical features of COVID-19 have been reported previously, data regarding the risk factors associated with the clinical outcomes are lacking. Objectives: To summary and analyze the clinical characteristics and identify the predictors of disease severity and mortality. Methods: The PubMed, Web of Science Core Collection, Embase, Cochrane and MedRxiv databases were searched through February 25, 2020. Meta-analysis of Observational Studies in Epidemiology (MOOSE) recommendations were followed. We extracted and pooled data using random-e□ects meta-analysis to summary the clinical feature of the confirmed COVID-19 patients, and further identify risk factors for disease severity and death. Heterogeneity was evaluated using the I 2 method and explained with subgroup analysis and meta-regression. Results: A total of 30 studies including 53000 patients with COVID-19 were included in this study, the mean age was 49.8 years (95% CI, 47.5-52.2 yrs) and 55.5% were male. The pooled incidence of severity and mortality were 20.2% (95% CI, 15.1-25.2%) and 3.1% (95% CI, 1.9-4.2%), respectively. The predictor for disease severity included old age (≥ 50 yrs, odds ratio [OR] = 2.61; 95% CI, 2.29-2.98), male (OR =1.348, 95% CI, 1.195-1.521), smoking (OR =1.734, 95% CI, 1.146-2.626) and any comorbidity (OR = 2.635, 95% CI, 2.098-3.309), especially chronic kidney disease (CKD, OR = 6.017; 95% CI, 2.192-16.514), chronic obstructive pulmonary disease (COPD, OR = 5.323; 95% CI, 2.613-10.847) and cerebrovascular disease (OR = 3.219; 95% CI, 1.486-6.972). In terms of laboratory results, increased lactate dehydrogenase (LDH), C-reactive protein (CRP) and D-dimer and decreased blood platelet and lymphocytes count were highly associated with severe COVID-19 (all for P < 0.001). Meanwhile, old age (≥ 60 yrs, RR = 9.45; 95% CI, 8.09-11.04), followed by cardiovascular disease (RR = 6.75; 95% CI, 5.40-8.43) hypertension (RR = 4.48; 95% CI, 3.69-5.45) and diabetes (RR = 4.43; 95% CI, 3.49-5.61) were found to be independent prognostic factors for the COVID-19 related death. Conclusions: To our knowledge, this is the first evidence-based medicine research to explore the risk factors of prognosis in patients with COVID-19, which is helpful to identify early-stage patients with poor prognosis and adapt effective treatment.


  • Watch out for the Thrombus Adhering to the Puncture Site of the Atrial Septum during Left Atrial Appendage Closure

    by Xuechao Tang, Xudong Xu, Hongwei Dou, Yuan Bai, Ni Zhu, Pan Li, Wenfeng Xiong, Yongwen Qin, Xianxian Zhao, Hong Wu

    We present a rare case of thrombus adhering to the puncture site of the atrial septum during left atrial appendage closure. By discussing the case, we suggest that some preventive measurements be taken during left atrial appendage closure and that conventional transesophageal echocardiography for the atrial septal puncture site be performed after the delivery sheath is removed.